Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Galecto

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Arab Health 2021

              Participation Not Confirmed

              Update your events

              Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences

              Contact the Supplier

              Lead Product(s): GB1211

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GB1211

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 15, 2020

              Details:

              GB1211 has been shown to be effective in several pre-clinical fibrosis models, without any signs of toxicity. Galectin-3 plays a key role in fibrosis development through cellular activation and production of collagen.

              PharmaCompass__DigitalAd